InflaRx (IFRX) Profit After Tax (2016 - 2026)
InflaRx's (IFRX) quarterly Profit After Tax came in at -$6.5 million in Q1 2026, up 25.13% year-on-year from -$5.2 million in Q1 2025, and up 46.98% quarter-over-quarter from -$12.3 million in Q4 2025.
InflaRx (IFRX) Profit After Tax (2016 - 2026) Analysis & Trends
InflaRx has disclosed Profit After Tax across 11 years of filings, most recently posting -$6.5 million for Q1 2026.
- Profit After Tax for Q1 2026 came in at -$6.5 million, up 25.13% year-over-year; the trailing twelve-month figure through Mar 2026 was -$49.5 million (down 2.62% YoY), and the FY2025 annual result was -$53.1 million, down 7.83% from the prior year.
- Profit After Tax came in at -$6.5 million for Q1 2026 at InflaRx, up from -$12.3 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $496582.6 in Q2 2022 to a low of -$7987.2 billion in Q3 2022.
- The 5-year median for Profit After Tax is -$11.9 million (2023), against an average of -$469.8 billion.
- Across the five-year window, Profit After Tax plunged 56183593.8% in 2022 and soared 100.0% in 2023, its largest moves.
- InflaRx's Profit After Tax stood at -$8.2 million in 2022, then slumped by 109.31% to -$17.1 million in 2023, then surged by 68.13% to -$5.5 million in 2024, then slumped by 126.07% to -$12.3 million in 2025, then soared by 46.98% to -$6.5 million in 2026.
- The last three Profit After Tax figures came in at -$6.5 million (Q1 2026), -$12.3 million (Q4 2025), and -$14.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.74 Mn |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | -6.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.55 Mn |
| Dec 31, 2025 | -12.35 Mn |
| Sep 30, 2025 | -14.33 Mn |
| Jun 30, 2025 | -16.32 Mn |
| Mar 31, 2025 | -8.75 Mn |
| Dec 31, 2024 | -5.46 Mn |
| Sep 30, 2024 | -19.16 Mn |
| Jun 30, 2024 | -14.91 Mn |
| Mar 31, 2024 | -10.49 Mn |
| Dec 31, 2023 | -17.14 Mn |
| Sep 30, 2023 | -8.11 Mn |
| Jun 30, 2023 | -8.93 Mn |
| Mar 31, 2023 | -11.90 Mn |
| Dec 31, 2022 | -8.19 Mn |
| Sep 30, 2022 | -7,987.22 Bn |
| Jun 30, 2022 | 496,582.57 |
| Mar 31, 2022 | -15.72 Mn |
| Dec 31, 2021 | -14.49 Mn |
| Sep 30, 2021 | -14.22 Mn |
| Jun 30, 2021 | 17.80 Mn |